Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors

Annals of Oncology

Volumn 24, Issue 1, 2013, Pages 252-257

  Dickson, M A ^a   Okuno, S H ^b   Keohan, M L ^a   Maki, R G ^a,c   D'Adamo, D R ^a,d   Akhurst, T J ^a,e   Antonescu, C R ^a   Schwartz, G K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Gastro intestinal stromal tumors; HSP90 inhibitors; Pharmacodynamics; Pharmacokinetics; Phase II trials; Sarcoma soft tissue malignancies

Indexed keywords

BIIB 021; FLUORODEOXYGLUCOSE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; NILOTINIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ABDOMINAL DISEASE; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME DEFECT; ENZYME INHIBITION; FAINTNESS; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERTENSION; IMAGE ANALYSIS; LEUKOPENIA; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NIGHT BLINDNESS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; RETINOL DEFICIENCY; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR NECROSIS;

ADENINE; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL STROMAL TUMORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; TREATMENT OUTCOME;

EID: 84871563835     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds275     Document Type: Article

References (15)

1. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007; 369: 1731-1741.
2. Wardelmann E, Thomas N, Merkelbach-Bruse S et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005; 6: 249-251.
3. Bauer S, Yu LK, Demetri GD et al. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006; 66: 9153-9161.
4. Lundgren K, Zhang H, Brekken J et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 2009; 8: 921-929.
5. Elfiky A, Saif MW, Beeram M et al. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience. J Clin Oncol 2008; 26 (Abstr 2503).
6. Zhang H, Neely L, Lundgren K et al. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Int J Cancer 2010; 126: 1226-1234.
7. Van den Abbeele AD. The lessons of GIST--PET and PET/CT: a new paradigm for imaging. Oncologist 2008; 13 (Suppl 2): 8-13.
8. Wagner AJ, Morgan JA, Chugh R et al. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial. J Clin Oncol 2008; 26 (Abstr 10503).
9. Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-1759.
10. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
11. Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group. Eur J Cancer 1999; 35: 1773-1782.
12. Dakappagari N, Neely L, Tangri S et al. An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors. Biomarkers 2010; 15: 31-38.
13. Zhang H, Chung D, Yang YC et al. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 2006; 5: 1256-1264.
14. Dewaele B, Wasag B, Cools J et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008; 14: 5749-5758.
15. Demetri GD, Le Cesne A, Von Mehren M et al. Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients ( pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. ASCO Gastrointest Cancer Symp 2010 (Abstr 64).